Research ArticleClinical Investigations
89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment
Sjoukje F. Oosting, Adrienne H. Brouwers, Suzanne C. van Es, Wouter B. Nagengast, Thijs H. Oude Munnink, Marjolijn N. Lub-de Hooge, Harry Hollema, Johan R. de Jong, Igle J. de Jong, Sanne de Haas, Stefan J. Scherer, Wim J. Sluiter, Rudi A. Dierckx, Alfons H.H. Bongaerts, Jourik A. Gietema and Elisabeth G.E. de Vries
Journal of Nuclear Medicine January 2015, 56 (1) 63-69; DOI: https://doi.org/10.2967/jnumed.114.144840
Sjoukje F. Oosting
1Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Adrienne H. Brouwers
2Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Suzanne C. van Es
1Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Wouter B. Nagengast
3Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Thijs H. Oude Munnink
1Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Marjolijn N. Lub-de Hooge
2Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
4Department of Hospital and Clinical Pharmacy, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Harry Hollema
5Department of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Johan R. de Jong
2Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Igle J. de Jong
6Department of Urology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Sanne de Haas
7F. Hoffmann-La Roche, Basel, Switzerland
Stefan J. Scherer
8Genentech, San Francisco, California; and
Wim J. Sluiter
5Department of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Rudi A. Dierckx
2Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Alfons H.H. Bongaerts
9Department of Radiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Jourik A. Gietema
1Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Elisabeth G.E. de Vries
1Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
In this issue
Journal of Nuclear Medicine
Vol. 56, Issue 1
January 1, 2015
89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment
Sjoukje F. Oosting, Adrienne H. Brouwers, Suzanne C. van Es, Wouter B. Nagengast, Thijs H. Oude Munnink, Marjolijn N. Lub-de Hooge, Harry Hollema, Johan R. de Jong, Igle J. de Jong, Sanne de Haas, Stefan J. Scherer, Wim J. Sluiter, Rudi A. Dierckx, Alfons H.H. Bongaerts, Jourik A. Gietema, Elisabeth G.E. de Vries
Journal of Nuclear Medicine Jan 2015, 56 (1) 63-69; DOI: 10.2967/jnumed.114.144840
89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment
Sjoukje F. Oosting, Adrienne H. Brouwers, Suzanne C. van Es, Wouter B. Nagengast, Thijs H. Oude Munnink, Marjolijn N. Lub-de Hooge, Harry Hollema, Johan R. de Jong, Igle J. de Jong, Sanne de Haas, Stefan J. Scherer, Wim J. Sluiter, Rudi A. Dierckx, Alfons H.H. Bongaerts, Jourik A. Gietema, Elisabeth G.E. de Vries
Journal of Nuclear Medicine Jan 2015, 56 (1) 63-69; DOI: 10.2967/jnumed.114.144840
Jump to section
Related Articles
Cited By...
- Spatiotemporal Heterogeneity across Metastases and Organ-Specific Response Informs Drug Efficacy and Patient Survival in Colorectal Cancer
- Spatiotemporal Response Heterogeneity Across Metastatic Lesions Informs Drug Efficacy and Patient Survival in Colorectal Cancer
- 89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake
- PET Imaging of Receptor Tyrosine Kinases in Cancer
- Molecular Imaging in Cancer Drug Development
- 89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors
- Theranostics Using Antibodies and Antibody-Related Therapeutics
- 89Zr-Bevacizumab PET: Potential Early Indicator of Everolimus Efficacy in Patients with Metastatic Renal Cell Carcinoma
- Tumor-Specific Uptake of Fluorescent Bevacizumab-IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study
- Molecular Drug Imaging: 89Zr-Bevacizumab PET in Children with Diffuse Intrinsic Pontine Glioma
- Radiation-Induced Enhancement of Antitumor T-cell Immunity by VEGF-Targeted 4-1BB Costimulation
- Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer
- 89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel-Lindau Disease
- Predictive Biomarkers for Molecularly Targeted Therapies in Renal Cell Carcinoma
- ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment
- Pretargeted Immuno-PET: Overcoming Limitations of Space and Time
- Molecular Fluorescence Endoscopy Targeting Vascular Endothelial Growth Factor A for Improved Colorectal Polyp Detection
- Harnessing the Power of Molecular Imaging for Precision Medicine
- Molecular Imaging of Post-Src Inhibition Tumor Signatures for Guiding Dasatinib Combination Therapy
- Antibody Positron Emission Tomography Imaging in Anticancer Drug Development